NEWS: MARCH 2005

-03/31/2005-

Inyx Inc. acquires Aventis Pharmaceuticals Puerto Rico Inc. To read article click here.

Cephalon Inc. submits NDA application to the FDA for approval of NUVIGIL™ (armodafinil). To read article click here.

Memory Pharmaceuticals Corp. moves forward MEM 63908 as a new drug candidate for the treatment of Alzheimer's disease. To read article click here.

Valentis Inc. initiates Phase IIb clinical trials of VLTS-934 for peripheral arterial disease treatment. To read article click here.

Rigel Pharmaceuticals Inc. completes Phase I clinical trials of R406 for rheumatoid arthritis treatment. To read article click here.

ImmunoGen Inc. submits IND application to the FDA for huC242-DM4 to treat several cancers. To read article click here.

-03/30/2005-

Press Release: Guava Technologies announces a new technical paper describing a novel flow cytometric type assay that provides rapid, accurate determination of Baculovirus titres. To read press release click here.

Elan Corp. and Biogen Idec Inc.'s clinical trials of Tysabri for Crohn's disease stopped due to second death. To read article click here.

FDA rejects Forest Laboratories Inc.'s application for Lexapro for social anxiety disorder treatment. To read article click here.

La Jolla Pharmaceutical to lay off 40% of its workforce since the FDA is not expected to approve Riquent for lupus renal disease treatment. To read article click here.

-03/29/2005-

Press Release: Approved for use in deep freezes and fully compatible with most centrifuges, the Mirror Rack from Porvair Sciences Ltd. provides a complete system that may be used for sample collection, transportation to the laboratory, sampling, and storage. To read press release click here.

Press Release: Available from Radleys Discovery Technologies (RDT) the Cooled Carousel Reaction Station range brings all the benefits low cost parallel synthesis to applications that require sub-ambient temperatures down to -70°C. To read press release click here.

Discovery Partners International Inc. and Chroma Therapeutics Ltd. form drug discovery collaboration. To read article click here.

Advancis Pharmaceutical Corporation to begin Phase III clinical trials of Amoxicillin PULSYS for the treatment of pharyngitis/tonsillitis. To read article click here.

Advanced Viral Research Corp. initiates Phase II clinical trials of AVR118 for cancer. To read article click here.

-03/28/2005-

FDA grants fast-track desingation to Theravance Inc.'s Telavancin for the treatment of Hospital Acquired Pneumonia. To read article click here.

Ligand Pharmaceuticals' Targretin fails lung cancer Phase III clinical trials. To read article click here.

-03/25/2005-

Pfizer and Coley Pharmaceuticals form alliance for the commercialization of anti-cancer toll like receptor drug ProMune for non-small cell lung cancer. To read article click here.

Genetronics Inc. receives US Patent 6,865,416 entitled "Electrically Induced Vessel Vasodilation." To read article click here.

FDA approves Millennium Pharmaceuticals Inc.'s drug VELCADE® (Bortezomib) for multiple myeloma. To read article click here.

FDA approves Roche and GlaxoSmithKline's drug Boniva® for postmenopausal osteoporosis. To read article click here.

Yamanouchi Pharmaceutical and Keio University discover a promising target molecule for obesity and diabetes treatment. To read article click here.

Nanogen Inc. receives U.S. Patent 6,867,048 entitled "Multiplexed Active Biologic Array." To read article click here.

-03/24/2005-

Telik Inc. to present update at the Lehman Brothers Global Healthcare Conference. To read article click here.

Adherex Technologies Inc. and Scynexis Inc. form collaboration to accelerate the design and development of Adherex's small molecule cadherin antagonist. To read article click here.

Guilford Pharmaceuticals Inc. halts clinical trials of Aquavan. To read article click here.

Protein Design Labs Inc. completes the acquisition of ESP Pharma Holding Company Inc. To read article click here.

Cara Therapeutics Inc. initiates Phase I clinical trials of CR665 for postoperative pain treatment. To read article click here.

Icoria Inc. sells its agricultural genomics assets to Monsanto Co. To read article click here.

-03/23/2005-

ICOS Corporation's Phase II clinical trials of phosphodiesterase 4 inhibitor IC485 for chronic obstructive pulmonary disease does not meet primary endpoint. To read article click here.

SEQUENOM Inc. discovers genetic variation in the gene encoding phosphodiesterase 4D (PDE4D) is linked to osteoporosis. To read article click here.

Pharmacopeia Drug Discovery and CV Therapeutics form cardiovascular disease drug discovery collaboration. To read article click here.

XenoPort Inc. initiates Phase I clinical trials of XP19986 for the treatment of spasticity and gastroesophageal reflux disease (GERD). To read article click here.

-03/22/2005-

Press Release: Porvair Sciences has announced a prime focus of its stand at the forthcoming Miptec 2005 conference in Basle, Switzerland (9th - 12th May) will be products that enhance sample integrity and minimise sample loss, evaporation and leakage during storage and transportation. To read press release click here.

Aphton Corporation to acquire Igeneon AG. To read article click here.

Gilead Sciences Inc. and Japan Tobacco Inc. form HIV alliance. To read article click here.

Researchers at Duke University's Comprehensive Cancer Center, discover selective small molecule inhibitor of cancer protein Icmt that is involved in the Ras pathway. To read article click here.

Saegis Pharmaceuticals Inc. inititates Phase II clinical trials of SGS742 for Attention Deficit Hyperactivity Disorder (ADHD) in adults. To read article click here.

The Gynecologic Oncology Group (GOG) initiates Phase III clinical trials of XYOTAX™ for ovarian cancer. To read article click here.

-03/21/2005-

Bayer Pharmaceuticals Corporation and Onyx Pharmaceuticals Inc.' s Phase III clinical trials of BAY 43-9006 shows delay progression of cancer in patients with advanced kidney cancer. To read article click here.

GlaxoSmithKline to license Theravance Inc.'s inhaled bifunctional, muscarinic antagonist/ beta2 agonist (MABA) program. To read article click here.

Trinity Biotech acquires Research Diagnostics Inc. To read article click here.

Novartis Pharma AG and Schering AG's anti colon cancer drug PTK/ZK fails to stop growth of tumors in Phase III clinical trials. To read article click here.